MATRix PROTOKOLÜ

Kaynaklar:

1-Ramsey, L. B., F. M. Balis, M. M. O'Brien, et al. 2018. "Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance." Oncologist 23(1):52-61. 

2- Thiel, E., A. Korfel, P. Martus, et al. 2010. "High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial." Lancet Oncol 11(11):1036-1047. 

3- Ferreri, A. J., K. Cwynarski, E. Pulczynski, et al. 2016. "Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial." Lancet Haematol 3(5):e217-227. 

4- Ferreri, A. J. M., K. Cwynarski, E. Pulczynski, et al. 2017. "Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial." Lancet Haematol 4(11):e510-e523.

5-Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 2015; 16: e322–32. 

6-Ferreri AJ. How I treat primary CNS lymphoma. Blood 2011; 118: 510–22.